OTHER (LOSS) INCOME, NET

9 Months Ended

Sep. 30, 2022

Other Income and Expenses [Abstract]

OTHER (LOSS) INCOME, NET

12. OTHER (LOSS) INCOME, NET

The following table summarizes other (loss) income, net for the periods indicated:

		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2022			2021			2022			2021
	(in thousands)
Interest expense		$	(14,736	)	$	(15,995	)	$	(46,560	)	$	(47,477	)
Interest income			4,780			148			7,362			259
Gain on contingent consideration, net*			6,700			7,200			6,700			7,200
Loss on debt extinguishment			(125,441	)		—			(125,441	)		—
Impairment of equity investment			—			(4,488	)		—			(4,488	)
Gain from sale of Priority Review    Voucher			—			—			—			102,000
Other expense, net			3,634			(314	)		(1,350	)		(656	)
Total other (loss) income, net		$	(125,063	)	$	(13,449	)	$	(159,289	)	$	56,838

* The gain on contingent consideration, net is related to the fair value adjustment of the regulatory-related contingent payments that are accounted for as derivatives. Please see Note 4, Fair Value Measurements for further details.

In February 2021, the Company the Company entered into an agreement to sell the rare pediatric disease Priority Review Voucher (“PRV”) it received from the FDA in connection with the approval of AMONDYS 45. Following the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in April 2021, the Company completed its sale of the PRV and received proceeds of $102.0 million, with no commission costs, which was recorded as a gain from sale of the PRV as it did not have a carrying value at the time of the sale. For more information related to the PRV, please read Note 4, Gain from Sale of Priority Review Voucher of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.